Remdesivir versus standard-of-care for severe Coronavirus disease 2019 Infection: an analysis of 28-day mortality

Remdesivir versus standard-of-care for severe Coronavirus disease 2019 Infection: an analysis of 28-day mortality

Background: Remdesivir is approved by the US Food and Drug Administration for the treatment of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been shown to shorten time to recovery and improve clinical outcomes in randomized trials. Methods: This was the final day 28 compa...

Full description

Bibliographic Details
Main Authors: Olender, Susan A., Walunas, Theresa L., Martinez, Esteban, Perez, Katherine K., Castagna, Antonella, Wang, Su, Kurbegov, Dax, Goyal, Parag, Ripamonti, Diego, Balani, Bindu, De Rosa, Francesco G., De Wit, Stéphane, Kim, Shin-Woo, Diaz, George, Bruno, Raffaele, Mullane, Kathleen M., Lye, David C., Gottlieb, Robert L., Haubrich, Richard H., Chokkalingam, Anand P., Wu, George, Diaz-Cuervo, Helena, Brainard, Diana M., Lee, I-Heng, Hu, Hao, Lin, Lanjia, Osinusi, Anu O., Bernardino, Jose I., Boffito, Marta
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Journal Article
Language:English
Published: 2022
Subjects:
Science::Medicine
Mortality
Remdesivir
Online Access:https://hdl.handle.net/10356/154077

Internet

https://hdl.handle.net/10356/154077

Similar Items